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INTRODUCTION 
In the modern era, Bronchial asthma is a disease that is becoming a 
major health issue in many developing countries. Increased urbanisation 
may have modified the traditionally low incidence of bronchial asthma in 
the third world
1
. Depressed socioeconomic conditions may supersede 
exposure to traffic-related pollution as a factor associated with asthma 
hospitalization. Although the incidence of new cases of asthma has 
decreased in recent years, the prevalence of asthma morbidity continues to 
be a significant clinical and public health issue. The measures of morbidity 
include the need for urgent medical care and high-dose asthma medications 
due to uncontrolled asthma symptoms. The word asthma means “panting” or 
“breathing hard”, it is derived from greek word  “aazein”. Asthma is more a 
clinical diagnosis than a laboratory diagnosis. 
Bronchial asthma and the resulting spasm was first described by   
Greek physician Hippocrates in 460-357 BC. That obstruction to bronchial  
airways lead to symptoms of asthma was put forth by  Greco-Roman 
physician  Galen in 130-201 BC. The occurrence  of  symptoms  does not  
simply  mean  constriction of  airways, it indicates  an underlying 
inflammatory process which  occurs as a result of  hyperresponsiveness of 
airways triggered by an allergen. This was discovered by asthma researchers 
in 1960
3
.                       
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In 2004, Masoli et al and the global initiative for asthma(GINA)  with 
combined data from the phase 1 International study of Asthma  and 
Allergies (ISACC) study conducted  in 1992-1996 and the European 
Community Respiratory Health Survey (ECRHS) in 1994-1998  generated 
the  global estimate of asthma burden, which suggested that the prevalence 
of asthma symptoms has  world wide variations
2
. This  report estimated that 
at present three hundred  million people were affected by asthma  world 
wide  and   by 2025 it would be around four hundred  million  with 
increasing urbanisation. 
Asthma accounts for around one percent of all Daily Adjusted Life 
Years lost in the world wide population, which comes to about 15 million 
per year. It reflects both the high prevalence and severity of 
asthma
6
(GINA2007,Mitchell 1987).The economic loss associated with 
asthma exceeds those of tuberculosis and HIV/AIDS combined. Improper 
asthma control is an important factor increasing the cost of subsequent 
treatment (Van Ganse et al. 2002). Asthma is associated with huge  
expenditures  in health care services which includes hospitalization and 
medications, loss of work in the form of  missed days of work/school that 
occurs during the  period of exacerbations  and  decline in future  earnings. 
Both these direct and indirect costs are associated with  morbidity and 
mortality. 
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Until the late 1800s, smoke was used as an agent to deliver 
medication into  lungs. In late 1800s, atropine was used to treat asthma. It 
was derived from  nightshade plant and  cigarette was used to deliver the 
atropine . The secret ingredients of the popular 19th century asthma cures 
were usually alcohol, cocaine or morphine. The first effective 
bronchodilator adrenaline was discovered by Jokici Takamine in 1901. In  
1960, anti-inflammatory medication  and   selective  short acting beta2-
agonists were born.  
         Initially pressurised MDI was utilised for delivering non-
selective beta-agonists adrenaline and isoprenaline. However, the significant 
number of asthma deaths that occurred in the 1960s led to these drugs being 
superseded by salbutamol, selective short-acting beta-agonist and 
beclomethasone, the first inhaled corticosteroid (ICS). 
Now a days salbutamol administration with metered- dose inhaler and 
spacer play a unique  role in treatment of acute severe  asthma. This study is 
an attempt to analyse the efficacy of  salbutamol  administration  by 
Metered Dose Inhaler-spacer compared to a  nebuliser in adults with acute 
asthma. 
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REVIEW OF LITERATURE 
DEFINITION 
According to American Thoracic society (1987) Asthma  is a clinical 
syndrome  characterized by hyperresponsiveness of  tracheobronchial tree to 
a variety of stimuli. The primary physiological manifestation of this is  
airway obstruction. The major symptoms of asthma are dry cough,  
paroxysms of dyspnoea and wheezing which may vary from mild  to severe 
and unremitting asthma (status asthmaticus). This can take the form of 
spontaneous variation in the severity of obstruction, substantial 
improvement in the severity of obstruction following bronchodilator or 
corticosteroid administration or increased obstruction caused by drugs or 
other stimuli like exercise and challenge test. 
EPIDEMIOLOGY
5 
Today in India, Bronchial asthma constitutes 0.5% of National burden 
of Disease. The total estimated prevalence of asthma in India is 3% (30 
million patients) and a median prevalence of 2.4% over the age of 15 
(Aggarwal et al 2006). According to National Family Health 
Survey(NFHS)-3 prevalence of asthma is higher in rural  than urban areas. 
In India, North East regions have the highest prevalence of asthma. In Tamil 
nadu the prevalence of asthma was 0.9% during  2005-2006.In childhood 
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asthma incidence is higher in boys than girls, but reverses in the age group 
of 15-50years and reverses again in the older age group where incidence 
among men increases once more. Prevalence of asthma among adults in 
India is similar in men and women. It increases steadily as age advances. 
Anatomy of the Lower airways-  
They extend from just below the vocal cords of the larynx to the 
respiratory bronchioles. The lower airways are branching, hollow 
passageways that conduct air to and from the alveoli. They  can alter their 
diameter which  allows them to regulate the speed at which air flows 
through them. In addition, the larger passages in the lower airways have 
cartilage rings and plates in their walls giving them some rigidity and 
preventing collapse .It consists of trachea, bronchi, respiratory bronchioles 
and alveolar ducts. Cartilaginous airways (trachea and bronchi) serve only 
to conduct air between external environment and the sites of gas exchange. 
Non-cartilaginous airways (bronchioles) serve both as conductors of 
inspired air and sites of gas exchange.  Terminal bronchioles are the 
smallest one and do not take part in gaseous exchange. 
The micro structure of the lower airways is as follows: 
 Mucosal layer is composed of pseudo stratified ciliated columnar epithelium 
and contains mucus secreting globlet  glands. 
 12 
 Submucosal layer contains seromucous glands which contributes to the 
mucous layer of respiratory epithelium. 
 Connective tissue in the submucosa  consists of elastin bands connected to 
the elastin networks of inter alveolar septa which is responsible for elastic 
recoil of the lung and the  muscle cells responsible for bronchoconstriction 
and relaxation. 
 Trachea and extra pulmonary bronchi has fibrocartilaginous or  fibroelastic 
tissue  forming the framework of connective tissue. 
Vascular supply  
The bronchi and bronchioles are supplied by the bronchial arteries 
which are derived from  thoracic aorta.  Bronchial artery branches supply 
the submucosa of  airways from the capillary plexuses  of  the muscle layer, 
by piercing it. Venules originating from these capillaries form venous 
plexuses by piercing back the muscle layer. Both arteries  and venules form  
plexuses around  the muscle layer. On constriction of bronchioles, arterial 
supply is maintained at systemic pressure but there is obstruction to the 
venous flow which leads to oedema formation in the bronchial mucosa 
during an attack of asthma. Pulmonary arteries supply the gas exchanging 
part of the lung. 
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Neural supply 
Both sensory and autonomic nerves contribute to sympathetic 
innervation. Sensory nerves  act as  afferents which begin as free nerve 
endings and also contain speciﬁc bronchial cells (DCGC) which act as 
neuroepithelial bodies. Autonomic nerves act as  efferents which cause 
broncho constriction, mucus secretion and vasodilation of bronchioles. 
Parasymphathetic  innervation is by vagus. 
Types of asthma  
1. Extrinsic/Allergic Asthma - This is the most common type and 
usually begins in childhood(90%).It is due to immunologic response to  
allergens (aeroallergen, pollens, dust mites, mold, animal dander, ingested 
foods, beverages or drugs).Type 1 Ig E mediated hypersensitivity reaction 
occurs in this type. It is characterized by positive family history and attacks 
preceeded by allergic rhinitis, utricaria or eczema. 
2. Intrinsic /non-atopic (Idiopathic asthma) This is the disease of 
adults (10%) and has a worse prognosis. It is due to endogenous factors like 
viral infection, chemical irritants, drugs(aspirin) and occupational factors. 
Atopy test is negative and there is no increase in the concentration of  
Immunoglobulin E. 
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3.   Nocturnal asthma 
This condition usually occurs in early morning hours. It  may also 
occur at night time. 
4. Occupational asthma
 
.
This is mainly due to pollutants in the environment where the person 
works and requires  prolonged  period of exposure
.
. The agents responsible 
are usually chemical fumes, wood dust and other irritants. 
5.  Seasonal asthma 
This type of asthma is aggravated in certain climates like spring than  
winter. Pollens which are released from the grass and flowers also 
contribute to this type of asthma.  
6.  Bronchial asthma 
This is a disease of the lungs in which the airways are stimulated by 
irritants. These irritants cause inflammation and mucus secretion which 
cause difficulty in gas exchange and leads to clinical symptoms like 
shortness of breath, dry cough and tightness of chest. 
7. Coughing Variant
 
 Dry cough  usually lasts for six to eight weeks in this variant. The 
airways undergo contracting spasms on exposure to the allergens and 
environmental irritants. It is common in children. 
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ETIOLOGY 
The etiology of asthma is complex and multifactorial. It is a 
heterogeneous disease with interplay between genetic and environmental 
factors. Twin studies(1971)and family history studies(1916 and 1924) done 
in  16 year old Finnish twins
4
 and their parents have reported  evidence of 
genetic connection between serum Ig E concentrations and increased 
respiratory sensitivity to acetyl choline and exercise challenge 
test.Monozygotic twins have increased risk than dizygotic twins. Sixty 
percent risk of atopy is there when  both parents are affected. Multiple 
interactions between  genes play an important role. The risk of developing 
asthma is greatest when both genetic and environmental factors are there. 
Genetic Factors- Polymorphism within IL-4(Ch.5q 31-33) ,IL-4R α ( ch 16)  
and  IL-13(ch-16) are  associated with allergic  sensitisation.Polymorphism 
in TNF is  responsible for inflammation rather than  allergic response. 
FcϵRI,IL-4,IL-13 and down regulation of  β2Adrenergic receptor gene 
polymorphisms (Arg16-Gly andGln27-Glu) are responsible for asthma 
severity.  After exposure to the agonist there is substitution of glycine for 
arginine at codon 16 resulting in increased down-regulation of β2-Adrnergic 
receptor . In contrast, a substitution  of glutamic acid for glutamine at codon 
27 attenuated down- regulation of β2-Adrenegic receptor. The 
polymorphism at codon 16 is associated with asthma severity, nocturnal 
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asthma, and airway hyperresponsiveness. It is not associated with fatal or 
near fatal asthma. 
Recent studies have shown that polymorphisms of ADAM-33 gene 
leads to increased inflammation by causing fibroblast and smooth muscle 
cell proliferation. This gene belongs to metalloproteinases family and is 
expressed by lung fibroblasts and bronchial smooth muscle cells. It is also 
associated with decline in lung function. Further studies are needed to 
determine the exact function of these genes ,gene-gene interactions and 
gene-environmental interaction which are undoubtedly complex and 
remains elusive for now
7
. 
Environmental factors 
In developing countries, the prevalence of asthma is increasing over 
the last few years indicating the importance of interaction between 
environmental and genetic factors. The  environmental factors like  
1. Out door pollutants(ozone, nitrogen dioxide and particles) 
2. Indoor pollutants(volatile organic compounds) 
3.  Diet rich in sodium , poly unsaturated fatty acids like linoleic acid 
and arachidonic acid  or low in antioxidants such as vitamins (A and 
C), magnesium, selenium, and essential fatty acids in marine and 
plant oils. 
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4. Viral respiratory infections 
5. Direct enzymatic effect of pollen allergens. 
Triggers of asthma
 
   Any condition that causes lower airway inflammation is called a 
trigger. Thus the inflammed  airways  contribute to the symptoms of asthma. 
Allergic triggers are also known as inflammatory triggers because it  causes 
inflammation of the lungs or spasm of the airway  musculature. They 
include dustmites, animals, cockroaches, moulds, pollens, viral infections 
and certain air pollutants. 
Symptom /non-allergic triggers do not cause inflammation but can  
stimulate irritant airways  especially if  they are  already inflamed. Symptom 
triggers include: smoke, exercise, cold air, chemical fumes and strong-
smelling substances like perfumes, food additives like sulphites, air 
pollutants and intense emotions. 
Histamine and other mediators which are released from  mast cells  
play a major event in early phases of asthma. In early and late  phases of 
asthma, macrophages and granulocytes also help in releasing  the mediators. 
Stretch and irritant receptors act as cholinergic motor nerves in the airways 
supplying mucosal glands and bronchial muscles. On triggering attack this 
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causes  smooth muscle contraction of the  airways  contributing to bronchial 
asthma.  This contraction is not uniform in all the airways. 
PATHOGENESIS
8 
 The triad of mechanism is as follows 
 AIRWAY INFLAMMATION 
 AIRWAY  HYPERRESPONSIVENESS 
 AIR FLOW OBSTRUCTION 
  Inflammatory macrophages, mast cells and dendritic cells residing in 
the airway epithelium have a unique role in initiating inflammatory and 
immune response. Granulocytes and lymphocytes  are immune blood-borne 
cells that get  recruited to  the inflamed asthmatic airways  and  play an  
additional role in the chronic inflammatory process including  air way 
hyperresponsiveness. 
Resident cells have low affinity receptors for IgE. During 
inflammatory response they secrete cytokines which act on the endothelial 
cells in the microvasculature to cause increased expression of selectin and 
integrin family groups, required for the entrapment and removal of  
leucocytes. After   the removal of granulocytes, monocytes transform into 
inflammatory macrophages in the tissue. These inflammatory macrophages 
secrete chemokines and cytokines which orchestrate the inflammatory 
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response. They also secrete enzymes and reactive oxygen species and the 
products of lipoxygenase and cyclooxygenase pathways. Both macrophages 
and dendritic cells (Antigen presenting cells) are able to cause  activation of  
T-lymphocytes. The myeloid Antigen presenting cells
 
are  likely to play a 
proinflammatory  role by expressing the antigen on  the surface of T 
lymphocytes.  On first allergen exposure it causes initial sensitisation and on 
repeated exposures it enhances the inflammation. The incremental and 
decremental response of inflammation depends on the exposure by the 
macrophages. The macrophages in the airspaces normally have  anti 
inflammatory effect on lymphocytes but this may be depressed in  asthma 
after exposure to an allergen .Thus macrophages have anti inflammatory 
response by preventing allergic inflammation. 
Mast cells being the source of histamine are found only in asthmatic 
airways. On allergen exposure they get activated and release preformed   
mediators apart from histamine like Prostagladin D2,Leukotreine C4, 
Tumour Necrosis Factor-α ,Vascular Endothelial Growth Factor which also  
contribute to  the inflammatory cascade. 
Circulating granulocytes 
Basophils secrete histamine due to the triggering effect of high 
affinity immunoglobulin E receptors on their surface. They are  also  
stimulated by  cytokines and  eosinophilic and neutrophilic chemokines.  
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Eosinophils are responsible for the development of hyper 
responsiveness of airways through the release of proteins, derived from 
secondary granules. The accumulation of eosinophils in the sensitised 
tissues is by  means of  eosinophilic  chemokines  and cytokine signals like 
Interleukin-5, eotaxin, Granulocyte Monocyte-Colony Stimulating Factor  
and RANTES. It differentiates asthma from other inflammatory conditions. 
Asthmatic individuals have high levels of circulating eosinophils and 
Charcot Leyden crystals in sputum, derived from the primary granules.  
Neutrophils are the resident cells in  lung parenchyma. In established 
asthma ,eosinophils are the predominant cells rather than the  neutrophils, 
but in acute  exacerbation neutrophil is the dominant granulocyte. In   
exacerbations of asthma neutrophil migration may precede eosinophil 
migration mediated by Interleukin-8. These  neutrophils are responsible for  
mucus secretion and increased vascular permeability  during exacerbations. 
Lymphocytes- In normal airways Th1 cells predominate. In asthmatic 
airways T cell  acts as a Th2 helper cell which  secretes Interleukin-4 for IgE 
production  from Immunoglobin G,Interleukin13 for hyperresponsiveness of 
airways and secretion of mucus and Interleukin-5 for eosinophil 
recruitment, activation and longevity. Recently it has been found that 
regulatory T cells have an immunosuppressive effect on T helper cells. 
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Antigen presenting cells are easily recognised by T helper cells which 
respond to them. 
A complex network of  mediators resembling  a spider’s web  is 
responsible for the  unique inflammatory and  immunologic response in 
asthma. Mediators like histamine, prostaglandins and leukotrienes have a  
pathogenic role in asthma. Kinins are bronchoconstrictors and also  
vasodilators. They also stimulate sensory nerve endings in the airways, 
cause exudation of plasma from the microvessels and  secretion of mucus in 
the airways. 
Lipid mediators- Cyclo oxygenase 2 products like Prostagladins D2,F2 
and Thromboxane A2 causes bronchoconstriction whereas  Prostaglandin D2 
enhances constrictor action of  histamine in asthmatics . Prostaglandin E2 
and prostacyclins have bronchodilator and anti inflammatory activity. 
Activation of 5-lipoxygenase by arachidonic acid pathway results in 
the synthesis of Leukotrienes B4, C4, D4 and E4. They are not preformed 
mediators.Leukotriene B4 is a neutrophilic chemoattractant. Leukotrienes 
C4, D4 and E4 are bronchoconstrictors, enhances hyperresponsiveness of 
the airways, facilitates  microvascular leakage and  enhances secretion. of  
mucus in the airways. 
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Platelet-activating factor is synthesized by inflammatory 
macrophages and granulocytes which causes bronchoconstriction and mucus 
secretion. It’s unique role in asthma is controversial. It induces leakage from 
the  microvessels. It’s inflammatory role along with other mediators, in the 
late asthmatic phase results in recruitment and degranulation of eosinophils. 
Cytokines, interferons and growth factors are secreted by 
inflammatory macrophages. They help in the immune and inflammatory 
processes by recruitment of inflammatory cells, amplification and  
ultimately its cessation. They also help in the regulation of  repair responses  
and  in   restoring the  tissue integrity. They are the key mediators in the 
chronic inflammatory process of bronchial asthma. 
Endothelins are potent vasoconstrictors and bronchoconstrictors. 
They are responsible for proliferation of smooth muscle cells  in chronic 
asthma. Nitric oxide is a potent vasodilator and bronchodilator that 
antagonises endothelin. They also provide free radicals which are 
responsible  for on going tissue damage. They  help in the amplification of 
Th2 cells in immune response and increases microvascular  leakage.
.
 
Growth factors play an important role in the chronic inflammatory 
process by proliferation of smooth muscle cells and remodelling of 
vasculature. Proliferation of fibroblasts and secretion of collagen is due to 
the effect of growth factors like fibroblast growth factor (FGF) ,Platelet-
 23 
derived growth factor  and Transforming growth factor b(TGF-b). Fibrosis 
of subepithelium is due to the thickening of basement membrane from  
deposition of collagen by  growth factors. 
Chemokines have chemoattractant property. C-X-C on chromosome 4  
is a neutrophilic  chemoattractant. Platelet factor 4 is not a  chemoattractant. 
Interleukin8 is specifically chemotactic for neutrophils.It is also an  
eosinophilic chemoattractant  in the presence of Interleukin-4 .The genes 
encoding the CC chemokine on chromosome 16( Regulated upon Activation  
Normal T cell Expressed and presumably Secreted)  is an eosinophilic 
chemoattractant. Macrophage derived chemokine (CCL-22) is involved in  
chemoattraction of helper 2 T cells. 
Events in the pathogenesis
8
. 
Early asthmatic response -Mast cells are triggered by cold air,changes 
in  the osmality of tissue fluid and exercise. Allergens attach to the surface 
of mast cells via Ig E receptors(FceR1).Antigen presenting cells activate  T 
lymphocytes which secrete Ig E which also triggers mast cells. After 
triggering , mast cells undergo degranulation and synthesise prostaglandins, 
leucotrienes, PAF, Tryptase
  
which result  in mucosal edema, mucus 
secretion and bronchoconstriction. 
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PATHOGENESIS 
EARLY ASTHMATIC RESPONSE 
 
2. Late asthmatic response-Inflammatory cells and immune cells   are 
responsible for the effects of inflammatory response. It comprises two 
phases  1.cell recruitment phase 2.effector mechanism phase.  
1. Cell recruitment phase-Recruitment of neutrophils into challenged 
airway, followed by recruitment of eosinophils and monocytes by means of 
chemotactic factors and chemotactic chemokines. Transmigration of 
granulocytes occurs as a multistep process, transient adhesion of 
granulocytes via adhesion molecules of selectin family and tight adhesion 
via integrin family
 
(ICAM-1&VCAM-1) followed by transmigration and 
emigration  of granulocytes into endothelial cells of  microvessels . The  
 25 
usefulness  of selective  adhesion  molecules is that it is responsible   for the 
specific accumulation  of eosinophils in response to allergy  and also for the 
variable timing   of recruitment of  inflammatory cells to  the  inflammed 
site  (monocytes and eosinophils  preceeded by neutrophils ). 
After recruitment these cells secrete histotoxic granules which 
produce endothelial injury, which contributes to the various effects  of 
inflammatory response.  They can also release wide range of ROI  including 
O2
-
, H2O2 and radicals of OH groups and secretes leukotrienes and 
prostanoids that causes increased mucus secretion, mucosal oedema  and 
narrowing of the airways. This reaction is responsible for    irreversibility of 
bronchodilation. Recent studies show that basophils rather than eosinophils 
are of importance in mediating the late phase response. 
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LATE ASTHMATIC RESPONSE 
CELL RECRUITMENT PHASE-I 
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PHASE-II  INFLAMMATORY RESPONSE AND ASTHMA 
EFFECTOR MECHANISMS. 
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Effects of inflammatory response
8 
1.Vascular responses 
Swelling of the mucosal membrane is responsible for increased 
narrowing and resistance of  the airways. This  inflammatory response is 
due to mediators causing increased vascular permeability  and exudation of 
plasma into the airway lumen. Increased blood flow in the bronchial arteries 
is  due to angiogenesis  by   inflammatory mediators like growth factors 
(VEGF, FGF, PDGF) and cytokines (Interleukin 1 and 8)  which result in  
reduction in the airway calibre. Remodelling of the airways  in chronic 
severe asthma may also be due to angiogenesis. Increased  blood ﬂow may 
help  in removing  inﬂammatory mediators from the airway. It may also be 
involved  in the development of exercise-induced asthma . 
2.  Epithelial injury and Shedding- 
Epithelial desquamation or denudation is a pathologic feature of 
asthma. It ranges from mild epithelial shedding to extensive  denudation. On 
exposure to asthmatic triggers, it may  lead to epithelial injury. It is mainly 
due to O2
-
,H2O2, OH groups  produced by the inflammatory cells and 
granular enzymes. Shedding of epithelium contributes to hyper 
responsiveness  of  airways. Epithelial damage which  allows penetration of 
allergens; loss of enzymes neutral endopeptidase  that degrade certain 
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peptide containing inflammatory mediators; loss of  epithelial-derived  
relaxant factor  and exposure of sensory nerves in the airways  leads to 
reflex neural effects on the airways. 
 
PATHOPHYSIOLOGY OF ASTHMA 
 
 
4.  Fibrosis 
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Subepithelial fibrosis is not only due to thickening of  basement 
membrane but also due to deposition of types III and V collagen below the 
true basement membrane and  is associated with eosinophil infiltration. The  
release of profibrotic mediators like   TGF causes inflammatory infiltration  
which results in  irreversible narrowing  of airways. 
5.Mucus Hypersecretion 
Increased mucus secretion by IL-4 and IL-13 contributes to the viscid 
mucous plugs that occlude asthmatic airways. Hyperplastic submucosal 
glands in the large airways and  hyperplastic  goblet cells in the epithelium 
are responsible for increased secretion  of mucus. Airway mucus is 
composed of Charcot Leyden crystals, creola bodies, albumin and mucin 
glycoproteins. 
6. Airway Smooth Muscle
 
 The abnormalities of smooth muscle in the airways may be due to the 
chronic inflammatory process. Inflammatory mediators are responsible for 
the  regulation  of  resting membrane potential by modulating ionic channels 
in the smooth muscle cells of peripheral airways. Thus it alters the level of 
excitability of these cells. Protein kinase C is activated by the inﬂammatory 
mediators in the airway smooth muscle cells. Down regulation of beta 
 31 
adrenergic responses in airway smooth muscle is due to the G- protein 
phosphorylation   coupling of  beta receptors to adenylyl cyclase. 
There is also a characteristic hypertrophy and hyperplasia of airway 
smooth muscle in asthmatic airways, as a result of stimulation of airway 
smooth-muscle cells by various growth factors such as platelet-derived 
growth factor (PDGF) or endothelin-1 released from inflammatory or 
epithelial cells. 
7. Neural Effects 
Defect in efferent (autonomic) nerve control leads to Airway 
hyperresponsiveness. Cholinergic pathways, through the release of 
acetylcholine acting on muscarinic receptors causes bronchoconstriction. 
Inflammatory mediators may activate sensory nerves, resulting in reflex 
cholinergic bronchoconstriction or release of inflammatory neuropeptides. 
Inflammatory products may also sensitize sensory nerve endings in the 
airway epithelium such that the nerves become hyperalgesic. Neurotrophins, 
released from different cells in the airways, including epithelial cells and 
mast cells, may cause proliferation and sensitization of airway sensory 
nerves. Airway nerves may also release neurotransmitters, such as substance 
P, which have inflammatory effects. 
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  Nuclear factor kappa B (NF-kB) is the factor responsible for 
transcription which plays a major event in bronchial asthma. Various  
stimuli can activate this factor, like the   activators of  protein kinase 
C,Interleukin-1b and TNF-alpha (They are the cytokines  which have an 
action on  proinflammation) and oxidants. It is the major factor of 
transcription which regulates the expression of inducible form of nitric 
oxide synthase, selectin and integrin groups, cytokines of proinflammation 
like Tumour Necrosis Factor-alpha,Granulocyte Monocyte Colony 
Stimulating Factor, Cyclo oxygenase-2  and  neutrophilic chemokines like 
Interleukin 8,Macrophage Inhibitory Protein -1a and eosinophilic 
chemokines. The above mentioned factors are the amplifiers of 
inflammation.     
PHYSIOLOGIC DISTURBANCES                                                                                                                                
The disturbances in function are most clearly caused  by narrowing of the 
airways. This narrowing is diffuse, affecting all levels of the 
tracheobronchial tree. Tests of airway function are abnormal. The resistance 
to the airflow is increased and maximal flow during expiration is also 
decreased  at all levels. Maximal inspiratory flow is also reduced. Residual 
volume of the lung is increased due to the  premature closure of peripheral  
bronchioles  at increased lung volumes. The adaptive advantages of 
breathing at higher lung volumes are increase  in the circumferential 
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traction—or "tethering" force—on intrapulmonary airways, tending to hold 
them open, and an increase in the elastic recoil of the lungs, increasing the 
driving pressure  for expiration. The work of  breathing is increased because 
of  the narrowing of the airways , decreased  compliance of the lungs and 
increase in thoracic cage volume. 
 This increased work must be performed by muscles of breathing -  
the diaphragm and intercostal muscles- and the accessory muscles (e.g., the 
sternocleidomastoids) are also brought into play. Fatiguability occurs due to 
increased breathing and this inappropriateness of the length-tension 
relationship in the muscles of breathing is perceived as  dyspnea.  
The airway narrowing in asthma also affects gas exchange. The 
obstruction of airways is not similar throughout the airways .Shifts in 
pulmonary blood flow cannot completely compensate for the 
underventilation of the regions of lung subtended by the most obstructed 
airways. The resulting ventilation  perfusion  mismatch widens the alveolar-
arterial oxygen difference [(A - a) PO2], and arterial oxygen tension in  
patients with acute severe asthma typically ranges between 60 and 69 
mmHg.  
CLINICAL FEATURES 
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The cardinal triad of bronchial asthma is chest tightness, wheezing, 
and shortness of breath on exposure to triggering factors, varying from day 
to day, within a day, with symptoms worsening at night. Throat tightness, 
choking, sniffed chest and chest congestion indicate the severity of 
bronchoconstriction. Non productive cough, nocturnal and chronic cough 
are also produced and worsened by triggers of asthma.Sputum production 
may also occur. 
Physical Examination 
Polyphonic expiratory wheeze is the most characteristic finding of 
asthma reflecting turbulent air flow in peripheral airways. Overinflation of 
thoracic cage results, due to adaptive response of breathing. Swelling and 
pallor of nasal mucosa indicate allergic rhinitis. Nasal polyps occurs in adult 
onset asthma. Sinus tenderness and purulent discharge indicates sinusitis. 
Obesity in addition reduces functional residual capacity. 
Course of illness 
Disease persistence and progression is mainly due to chronic 
inflammatory process. Inspite of anti-inflammatory therapy eosinophilic 
infiltration  and remodelling  of the   bronchial epithelium  contributes to the 
persistence and progression of disease. Even in the quiescent phase, helper 
T2 cells  in the airways are active. Activation of Transforming growth factor 
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Beta by metalloproteinases which stimulates IL-13 to promote fibrosis is 
also responsible for epithelial injury,eosinophilia and  secretion of mucus. It 
is the key effector cytokine in asthma. The inflammatory response is  
augmented by Interleukin-13 and other Th2 cytokines produced  by non-T 
cells .Amplification  of inflammation is  by the  cytokines, proteases and 
chemokines which are derived from fibroblasts, smooth muscle and local 
epithelial responses .Adenosine produced by the injured cells enhances IL-
13 production
9
.  
Factors important for persistence  and progression of asthma are
10 
1. Sex 
It shows significant relation to the deterioration of pulmonary  
function in patients with persistent asthma. The severity of asthma  is more 
in females  due to the frequent hospital admission  and prolonged hospital 
stay during an  acute attack. Poor prognosis is common in females. Young 
females are more prone for Non atopic asthma.  
2. Smoking 
Passive exposure to cigarette smoke in childhood is a risk factor for 
wheezy bronchitis, airway hyperresponsiveness, and symptomatic asthma. 
Active smoking was a predictor of lower FEV1 %  in early adulthood in 
patients with nonatopic asthma. In  adults, the rate of decrease in lung 
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function over time, as measured by FEV1is greater in those with asthma 
than in healthy subjects. Moreover, the rate of decrease among smokers is 
greater in those with asthma than in those without asthma. 
3. Age of onset 
Respiratory symptoms occuring for the first time at an older age  had  
a good  prognosis as  indicated  by  Forced Expiratory Volume in 1 second  
in children with non atopic asthma .In contrast ,no such relation exists in 
atopic asthma.  
4. Duration of  Illness 
 Increased airway vulnerability due to unopposed inflammation play a 
unique role in the deterioration of pulmonary function  in recently diagnosed 
asthma. In chronic cases, chronic inflammatory process leads to decline in 
the lung function due to progressive airway remodelling. 
5. Atopy
 
In non atopic asthmatic population, chronic inflammation is 
considered to be one of the risk factor in the decline of lung function. 
Several follow up studies in atopic asthmatic individuals show that there is a 
negative relationship between atopy and  outcome of lung function. Chronic 
inflammatory process is responsible for the progression of disease 
irrespective of atopic status. 
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6. Severity of symptoms
 
  
Severe persistent asthma and increased frequency of symptoms are 
associated with decline in lung functions like Forced Expiratory Volume in 
1second and Forced Expiratory Volume in1 second /forced vital capacity 
ratio. Several studies have concluded that both the  severity and frequency 
of illness  are  associated with a poor prognosis in asthmatic individuals. 
Growth of the individual is also affected by this. 
 
6.  Level of Lung Function   
  Initial (prior to diagnosis) decline in the pulmonary function is an 
indicator  of  further deterioration  of pulmonary function. Low level of lung 
function is an independent factor for disease progression  in asthma. 
7.  Airway  hyperresponsiveness  
Bronchial hyperresponsiveness is one of the factors responsible for 
inflammatory response in asthma. Hyperresponsiveness of bronchial 
airways predicts low levels of FEV1 in adolescent individuals .This was 
observed in population studies. Thus airway hyperresponsiveness is 
associated with both impaired attainment of  pulmonary function in children 
and accelerated deterioration of pulmonary function in adults.  
8.  Response to Bronchodilators
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The most  important characteristic feature of asthma is positive  
reversibility test. It occurs  with beta 2 agonist  (broncho dilators). Excess 
response to bronchodilators is one of the  risk factors for worst outcome.  
9.  Blood  Eosinophilia  
Presence of  eosinophila,  eosinophilic cationic protein and IL-5  in 
the  peripheral blood are  related to the severity of presenting  asthma  and 
denotes an unfavourable outcome with respect to decline in  lung function in 
asthmatics.  
10. Daily   secretion  of mucus  for more than three months  in one year   
for  at least  two consecutive years  indicates chronic inflammatory process 
in the airways. Prolonged periods of hypersecretion of mucus in asthmatic 
individuals  lead to an accelerated deterioration  of pulmonary  function.  
11.Anti inflammatory Drugs 
Minimizing the degree of airway inflammation may lead to a more 
favourable growth of lung function in children with asthma. Anti-
inflammatory therapy, especially treatment with  inhaled corticosteroids, not 
only effectively improves the  clinical severity  of asthma but also  reduces 
the chronic inflammation  in the airways of asthmatic patients. 
 
Classification of asthma
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Assessment of severity and clinical pattern of asthma is needed  in  
recently  diagnosed asthmatic patients to initiate the  treatment and to  
decrease exacerbations. 
 A recently diagnosed asthmatic patient is classified   according to: 
 the frequency and severity of symptoms 
 spirometric assessment  and reversibility with bronchodilators. 
Intermittent asthma 
  Asthmatic  symptoms   occurs weekly once during morning hours. 
  Asthmatic symptoms  occurs  monthly once  in nocturnal period. 
 Acute episodes occurs  infrequently and  for short periods. 
 Forced Expiratory Volume in1second is at least  more than  eighty 
percent of predicted and varies by less than twenty percent. 
Mild persistent asthma 
 Asthmatic Symptoms occurs more than twice a week  during 
morning hours but not every day. 
 Asthmatic symptoms occurs more than twice a  month in nocturnal 
period, but not every week. 
 Acute episodes occur occasionally and may affect activity or 
sleep. 
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  Forced Expiratory Volume in one second  is at least Eighty 
percent predicted  and the variability by twenty to thirty percent. 
Moderate persistent asthma 
 Asthmatic symptoms occurs every day during daytime, but do not 
affect regular activity. 
 Asthmatic symptoms  occur  once a  week in  nocturnal period. 
 Acute  episodes  occurs  occasionally  and  can  affect regular 
activity. 
  Forced Expiratory Volume in one  second is sixty to eighty percent 
predicted and the variability is more than thirty percent . 
Severe persistent asthma 
 Asthmatic symptoms occurs daily during morning hours and affect 
day to day activity. 
 Asthmatic symptoms  occurs daily in nocturnal period. 
 Acute episodes occur  frequently. 
  Forced Expiratory Volume in one second is sixty percent or less than 
predicted , and  the variability is  more than thirty percent. 
Complications 
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1. The most common complication is due to long term steroid use. 
Esophageal candidiasis is a common side effect of inhaled 
corticosteroids therapy.
 
2. Infections continue to irritate the damaged lung airways,causing it to 
swell and produce more mucus.  Illnesses such as bronchitis, 
pneumonia, tuberculosis, compounded with asthma can be a deadly 
combination. H1N1, seasonal influenza, avian influenza, and RSV 
can also be a deadly mix. Allergic bronchopulmonary aspergillosis 
(ABPA) occurs in patients with asthma resulting in pulmonary 
infiltrates, thick mucus plugs that contain hyphae of Aspergillus 
fumigatus, elevation of total serum IgE concentration and peripheral 
blood and sputum eosinophilia
17
.  
3. Breathing disturbances lead to night awakening, signs of snoring and 
sleepiness during the daytime. Another problem with asthmatics is 
that they develop sleep apnea due to irregular breathing pattern. 
4.  Pneumothorax is a condition where air leaks out of the lungs. In 
asthma, it may be caused by the rupture of overstretched alveoli or air 
sacs in the lungs. Pneumomediastinum may be suspected in an 
asthma patient who complains of substernal chest pain during an 
asthma attack and having subcutaneous emphysema in the neck and  
chest and with Hamman’s sign on auscultation18.  
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5. Segmental collapse of lung occurs due to impacted  mucus  plug
20
. 
6.  Severe coughing episode may lead to a fractured rib, urinary 
incontinence in women and fecal incontinence in men or women. 
7. Long-standing chronic severe asthma occasionally leads to 
development of pulmonary hypertension and corpulmonale, and 
chronic hypercapnia.
 
8. Status asthmaticus is a life threatening complication of asthma. 
Status asthmaticus 
 
is an acute  exacerbation of asthma that does not 
respond to standard  treatment with  bronchodilators and steroids  and  is 
associated with symptoms of potential respiratory failure. Poor control of 
allergens or asthma triggers in the home and/or workplace ,post viral 
infection, exercise in a cold environment, poor adherence to anti-
inflammatory therapy are the risk factors for this attack. Small bowel 
infarction with pneumatosis intestinalis occurs in the early course of life-
threatening severe acute asthma
19
. 
Levels of severity of acute asthma exacerbations 
11
  
Moderate asthma with exacerbation- 
 Increasing asthma symptoms 
 Peak Expiratory Flow Rate more than Fifty to seventy percent. 
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 No features suggestive of  increased severity of  asthma.  
Acute severe Asthma- 
 Peak Expiratory Flow Rate Thirty three to Fifty percent  of  best or 
predicted 
 Respiratory rate more than twenty five per minute. 
 Heart rate  more than one hundred and ten per minute. 
 Patient is not able to complete sentences in one breath 
Life threatening Asthma 
The clinical features  are as  follows 
 Signs of manifestations                        Measurements  
Altered  mental status                 Peak Expiratory Flow rate less than thirty                   
Fall in Blood pressure               three percent of best or predicted                                          
Cyanosis                                    Oxygen saturation less than ninety two percent 
Silent chest                                Pa O2  less than 8 kPa 
Increase  in heart rate               “Normal” Pa CO2 (4.6–6.0 kPa)  
Poor respiratory effort    
Exhaustion 
  Near-fatal asthma   
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  Partial pressure of carbondioxide is increased. 
 It requires life saving measures  like  mechanical ventilation with   increased 
inflation pressures. 
Treatment  
1. Oxygen –Six to eight  Litres /min  of  high flow  oxygen  is necessary 
and  is monitored  by pulse oximetry. In severe attack, it is necessary 
to monitor  arterial Pa O2,PaCO2,  pH and  SaO2. 
2.  Beta 2 agonists –   beta 2 agonists have a  unique role   in relieving 
the clinical symptoms and improving the lung function in acute 
episodes. 1- 2 mL of salbutamol  solution (each ml contains 5 mg of 
salbutamol) with 2 mL of saline via nebuliser is necessary. Frequency  
of dosing will depend upon clinical response, and  if there is no 
response, the dose is to be titrated.A dose of 12 puffs (via MDI with 
Spacer) is equivalent to a 5 mg nebulised salbutamol.Intravenous 
route in status asthmaticus is controversial.
 
3. Nebulised ipratropium bromide –Combination therapy of 500 µg of 
ipratropium bromide with salbutamol via nebuliser for every 2 hours  
is recommended for severe attacks. 
4.  Systemic steroids
 
- 250 mg  of IV hydrocortisone  is to be given as a 
starting dose followed by 250mg  sixth hourly for the first twenty four 
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hours.  In moderate attack one milli gram per kilogram body weight 
of prednisolone  can be given orally and in a mild attack oral steroids 
can be given. 
5.  IV aminophylline – The role of this drug  in acute asthma is 
controversial.  
6. Adrenaline –In anaphylaxis adrenaline 0.5 mL of one in one thousand 
dilution can be given by intramuscular route. In case of respiratory 
arrest  five milli litre of one in ten thousand dilution can be given 
slowly by intravenous route.   
There is no further clinical evidence to support the use of  other 
emergency therapeutic measures like heliox for nonintubated patients. The 
role of noninvasive procedures like positive pressure ventilation in patients 
with status asthmaticus
12
is controversial .Further studies are  needed for 
these. 
Differential Diagnosis
 
1. Vocal cord dysfunction21 is due to abnormal vocal cord adduction 
during inspiration. It may disappear with panting, speech, or laughing. 
Patients present with chronic symptoms suggestive of asthma, normal 
spirometry, poor response to asthma medications. The diagnosis can be 
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made using direct laryngoscopy  but only during symptomatic periods or 
after exercise. 
2. Tracheal and bronchial lesions-Airway tumors (endobronchial 
carcinoid and mucoepidermoid tumors) are reported to manifest with 
symptoms similar to those of asthma and may be differentiated by 
persistence of symptoms; and associated voice changes, haemoptysis or 
weight loss .On physical examination a fixed monophonic inspiratory 
wheeze or stridor is heard. Other  tracheal lesions include bronchocentric 
granulomatosis, subglottic stenosis, subglottic web, tracheal hamartoma, 
bronchogenic cysts, leiomyoma, and tracheobronchopathia osteoplastica. 
3.  Aspiration  of  foreign body  can  cause   both  focal  and  generalised 
wheeze. It occurs in children  and in middle aged people. 
4. Pulmonary embolism, pulmonary infiltrates with eosinophilia, drug 
intake (ACE inhibitors) may mimic bronchial asthma. 
5.  Pulmonary migraine occurs due to the obliteration of  lobar bronchus. 
It is characterised by migraine headache, recurrent attacks of asthma and 
atelectasis. In case of atelectasis of unknown eliology, pulmonary migraine 
should be thought of.  
6. Congestive heart failure is characterized by dyspnea not preceeded by 
cough, presence of S3, basal rales and wheezing. It occurs due to dilatation 
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of pulmonary vasculature and edema of the intersitium which causes decline 
in the compliance of lung which  leads to  symptoms like asthma.  In cardiac 
asthma  wheezing occurs intermittently and during night time due to the 
spasm of bronchioles. 
7. Diffuse panbronchiolitis may mimic symptoms of bronchial asthma 
like coughing, dyspnea on exertion,wheezing  and sinusitis
. 
High-resolution 
CT is usually done to differentiate it from asthma. 
8.  Sinusitis in toddlers, can be  associated with the symptoms of  asthma  
9.  Gastroesophageal reflux (GER) may mimic asthma symptoms like 
dry cough, recurrent bronchitis, pneumonia, wheezing, and asthma. 
10.  Anomalies of arch of aorta can occur  in middle age period  which 
may simulate exercise-induced asthma. 
11.  Endobronchial tuberculosis simulating symptoms of  bronchial  
asthma. 
12 Extrinsic conditions like mediastinal lymphadenopathy from 
Hodgkins  lymphoma   can contribute to symptoms like asthma.   
Aspirin or NSAID hypersensitivity and reactive airways dysfunction 
syndrome may be mistaken for asthma. 
Though COPD closely mimics asthma, reversibility test  
differentiates it from asthma. A significant smoking history greater than 20-
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pack years should   strongly favour  chronic obstructive pulmonary disease 
(COPD) rather  than asthma. 
Obstructive and restrictive lung diseases share  the same main clinical 
features. They are identified using pulmonary function tests, Chest X-ray 
and  CT scan  of the chest. 
Investigations- 
1. Blood eosinophil count- To exclude tropical pulmonary eosinophilia. 
2. Sputum for AFB and Eosinophil : To exclude pulmonary tuberculosis 
and pulmonary eosinophilia. Sputum for Churchman’s spirals 
(mucous that forms a cast of the small airway) and for Charcot Laden 
crystals (breakdown products of eosinophils)  
3.  Blood glucose to exclude Diabetes mellitus. 
4.  ECG/Echocardiography to exclude cardiac diseases. 
5.  Chest X-ray P/A view :usually normal in asthma. To exclude COPD, 
Pulmonary tuberculosis, Consolidation, Pneumothorax, Pulmonary 
oedema, Tumor, FB in airway etc. 
6. Blood gas analysis- At the beginning of an asthmatic episode there is 
a fall in the partial pressure of oxygen and carbondioxide  but the pH 
rises. Due to the deterioration  from  the disease  the  partial pressures 
of oxygen and carbondioxide  fall continuously whereas the pH rises . 
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At one stage the lungs are not able to wash out the  carbon dioxide 
and then the  partial pressure of carbon dioxide and pH start rising but 
the partial pressure of oxygen falls continuously. As the disease 
becomes very worse the  partial pressure of  carbondioxide  and the 
increased pH comes back to their normal level. 
7.  Skin hypersensitivity test - To determine the cause of asthma. 
8. Blood Ig E Extrinsic Asthma, Blood Ig A  Intrinsic Asthma   
 andaspergillus  Ab. 
9. Pulmonary Function Test
 
  Pulmonary function tests are a group of procedures that measure the 
function  of  lung (inhalation and exhalation of air and exchange of 
gases).These tests can measure response to bronchodilators, examine the 
effect of exercise, and measure variability over a period of days or weeks, 
with or without a course of  steroids and  assess the effect of challenge 
testing. It can demonstrate an obstructive pattern, the hallmark of which is a 
decrease in expiratory flow rates : reduction in  forced expiratory volume 
over 1 sec (FEV1) and a proportionally smaller reduction in the forced vital 
capacity (FVC) and decreased FEV1/ FVC ratio (generally <0.70). The 
clinical diagnosis of asthma is supported by an obstructive pattern that 
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improves after bronchodilator therapy. Zang M, et al reported that 
symptoms, FEV1/FVC, and peak flow are indices of the control of asthma. 
Peak flow meter    
It  is a  instrument  of portability that measures maximum speed of 
expiration ( peak expiratory flow rate). The peak expiratory flow rate is the 
maximal rate at which a  person can exhale during  a  maximal expiratory 
effort after a deep inspiration. In patients with asthma, the PEFR percent 
predicted correlates well with the percent predicted value for the forced 
expiratory volume in one second (FEV1).  It can help recognize early 
changes (often hours or even days) before  the signs of worsening asthma 
show. 
PEAK FLOW METER 
                             
 Merits of Peak Flow Meter: 
  Identification of asthma severity. 
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 During an  exacerbation ,to  check the therapeutic response.  
 The therapeutic response of chronic asthma can be monitored by the       
course of  disease. It provides information regarding changing  of treatment. 
 It identify  the worsening of  pulmonary function and avoid frequent 
exacerbation. 
A Peak Expiratory Flow Rate  lower than  predicted  level  indicates  
narrowing of airways or a decline in the volume of lung . These features are 
the characteristic features of obstructive lung disease. 
 Bronchial  asthma is confirmed  by 
 Test of reversibility. 
 Variability of Peak Expiratory Flow Rate in a day is greater than 
twenty percent. 
 After running or exercise the decremental response of peak expiratory  
       flow rate is fifteen percent or greater. 
The variability of Peak Expiratory Flow Rate is the difference 
between the highest and lowest value in twenty four hours. The lowest 
values of  Peak Expiratory Flow Rate is  expressed in  percentage . Diurnal 
variability  of  Peak Expiratory Flow Rate  is common. The highest  level of 
Peak Expiratory flow rate  usually occurs in the afternoon  and the lowest 
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level in  the early morning hours. A variability of Peak Expiratory Flow rate 
more than twenty percent is the diagnostic feature of asthma. A higher 
variability of  Peak Expiratory Flow Rate indicates an increase in severity
 
of 
asthma .Rise  in peak  Expiratory flow rate   more than  twenty percent  after 
the administration   of   bronchodilator  indicates positive reversiblity test. It 
is a diagnostic test of bronchial asthma and  has been reported in the study 
of  Dekker et al
14
. 
Procedure :   Blow  into the Peak Flow Meter with force. This is  repeated 
thrice  and the best reading is to be recorded. 
The Steps are as follows- 
•  The Device should  read zero or be at base level before the procedure. 
•  Standing  up (unless you have a physical disability)position is best for 
doing the procedure. 
•  The breath  is  to be taken as deep as possible 
•  The meter is  to be kept  in  mouth and  lips  to be closed around the  
mouthpiece 
•  Air to be blown out into the meter  as quick and  hard   as possible  for1  
to 2  seconds 
•  Coughing, spitting or  tongue itself can  block the mouthpiece 
• The readings  are to be recorded. 
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• The procedure  is  to be repeated  two times, and  the highest of  the three  
values  is  to be recorded. 
According to the American Lung Association  the readings of peak 
flow meter are classified into three zones. Asthma management plan is 
based on these three  zones. 
Green zone:   
Peak Expiratory Flow Rate is eighty to hundred percent of personal 
best. It indicates that the asthma is under good control.  
Yellow zone: 
Peak Expiratory Flow Rate is Fifty to Eighty percent of personal best. 
It indicates caution. It means respiratory airways are narrowed and 
additional medication may be required. 
Red zone: 
Peak Expiratory Flow Rate below Fifty percent of personal best. It 
indicates a medical emergrncy.Severe airway narrowing may be occurring 
and immediate action is to be taken. 
Spirometry
13
 (meaning the measuring of breath) is the most common 
of the pulmonary function tests (PFTs), measuring lung function, 
specifically the amount (volume) and/or speed (flow) of air that can be 
inhaled and exhaled as demonstrated by kath Cooper et al. 
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The more common lung function values measured with spirometry 
are Forced vital capacity (FVC), Forced expiratory volume (FEV), Forced 
expiratory flow 25% to 75%,Peak expiratory flow (PEF),Maximum 
voluntary ventilation (MVV),Slow vital capacity (SVC) Total lung capacity 
(TLC), Functional residual capacity (FRC),Residual volume (RV). 
Expiratory reserve volume (ERV). 
 
SPIROMETRY 
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Preparation Before the test 
1.  Refrain from smoking within  1 h of testing 
2. Avoid consuming alcohol within 4 h of testing 
3. Avoid performing vigorous exercise within 30 min of testing 
4. Avoid wearing clothing that substantially restricts full chest and 
abdominal expansion 
5. Avoid eating a large meal within 2 h of testing 
6. Wear denture if you have it.  
According to British Thoracic Society  in 1994  
The procedure is as follows: 
1.   The individual to be  seated  in an  armed chair. 
2. At the beginning, 2 values of vital capacity in relaxed position to be 
tested  succeeded by 3 FVC values. Leakage of air is prevented by using 
nasal clips. 
3. The individual is instructed to take a deep breath before the 
procedure. 
4.   To prevent air leakage, tight sealing  of instrument  is to be done.          
5. The vital  capacity can be measured in two ways. In relaxed position, 
the individual to  breath out in a slow speed. This gives the measurement of 
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relaxed Vital Capacity. For Forced Vital Capacity, before the test the 
individual should inspire completely  and then  should  blow  out fast, hard   
and  continuously  in order to exhale  all the air.         
6. It will take 6s to do FVC, But it can take up to 15s in some patients 
with obstructive breathing patterns ; Leave at least 30s between the  blows  
for the  recovery of the individual. At one time the individual can try three 
to eight blows. 
Select the best results of  FEV1 and FVC from three reproducible  
blows. Calculate the FEV1/FVC ratio  from the best VC reading. 
FEV1-The amount of air which can be forcibly exhaled from the 
lungs in the first second of a forced exhalation. It is reduced in both 
obstructive and restrictive disease.  mild: FEV1 ≥80% predicted; moderate: 
FEV1 50 to <80% predicted; severe: FEV1 30 to <50% predicted; very 
severe: FEV1 <30% predicted. 
Reversibility is demonstrated by a >12% and 200-mL increase in 
FEV1 15 minutes after an inhaled short-acting Beta 2-agonist or 2 to 4 week 
trial of oral corticosteroids (OCS) (prednisone or prednisolone 30–40 mg 
daily).  
FVC- The amount of air forcibly exhaled from the lungs after the 
deep inspiration.   FVC is usually normal  in obstructive  disease and   
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decreased if  there is trapping of air. FVC is  decreased in restrictive disease. 
Forced Expiratory Ratio is the percentage of forced Vital Capacity  expelled 
in the first second of a forceful expiration.  In restrictive disease it is usually 
within normal limits  and  decreased  in obstructive disease. 
The flow-volume loop (also called a spirogram) is a plot of 
inspiratory and expiratory flow (on the Y-axis) against volume (on the X-
axis) during the performance of maximally forced inspiratory and expiratory 
manoeuvres. It is not considered as a primary diagnostic aid. 
Provocative Test
 
Challenge tests are the provocative measures to identify the 
responsiveness of bronchial airways by inhaling the  substances  causing the 
symptoms of asthma. During this procedure, inhalation of substance occurs 
via nebulizer. The substances are delivered in aerosolised form  through the 
face mask or mouth piece. Substances like methacholine or mannitol can be 
used. The measurements are recorded by spirometry to evaluate pulmonary 
function prior, during and after the procedure. 
Stress tests are done to assess the effect of stress like exercise  on   
pulmonary function tests. The values are recorded by spirometer after the 
stress test  and then again at resting state. 
Treatment 
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Aims of Asthma Therapy 
1. Chronic symptoms to be minimal including nocturnal  
2. Minimal exacerbations. 
3. No emergency visits.  
4. Use of  beta2-agonist to be minimal 
5. No limitations of activities, including exercise. 
6. Peak expiratory flow circadian variation <20%. 
7. Normal PEF  
8. Minimal adverse  effects from medication. 
Approach to management 
i. Education of  patient and family  
ii.  Avoidance of  precipitating factors  
iii.  Use of the lowest effective dose of convenient medications 
minimising short and long term side effects.  
iv.  Assessment of severity and response to treatment 
1. Education of patient and family
 
Ensuring the patient’s cooperation and compliance with therapy, 
avoidance of triggers, proper use of inhaled drugs, proper use of peak flow 
meter, recognition of features of worsening asthma and side effects of drugs. 
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2. Lifestyle modification 
Avoidance of triggers is a key component of improving control and 
preventing attacks (smoking, aspirin, beta blockers, NSAID, allergen, 
occupation, atmospheric pollution, food, exercise and cold air). 
 
3. Medications- 
The main drugs for asthma can be divided into bronchodilators, 
which give rapid relief of symptoms mainly through relaxation of airway 
smooth muscle and anti inflammatory drugs   which inhibit the underlying 
inflammatory process. 
There are three classes of bronchodilators currently in use:beta2-
adrenergic agonists, anticholinergics, and theophylline. Of these, beta2-
agonists are by far the most effective. 
Bronchodilators 
Short-acting bronchodilators are also called "quick-acting," 
"reliever," or "rescue" medications. These medications relieve  symptoms of 
acute exacerbation.. They are salbutamol, terbutaline and fenoterol. The 
long-acting bronchodilators  can be used twice daily  to  control asthma. 
They do not  give quick relief  in acute exacerbation. They should  be used 
only in combination with inhaled steroids for long-term control of asthma 
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symptoms. They are salmeterol and formoterol. Bronchodilators (Beta 2 –
agonist) act on bronchial smooth muscle and reverse bronchoconstriction, 
inhibits mast cell mediator release,inhibits  plasma exudation and airway 
edema,increased mucociliary clearance,decrease mucus secretion, decrease 
cough and have no effect on inflammation.Mode of delivery is by 
oral/inhalation. Oral forms of bronchodilators have more systemic 
absorption  compared  to  inhalers  and they   tend to have more systemic  
side effects.  
Contrary to this, bronchodilators delivered with inhalers  enter 
directly into the peripheral  airways rather than systemic circulation and 
have fewer side effects. Regular treatment with bronchodilators is to be 
avoided because of increased development of bronchial hyper 
responsiveness. Asthma severity can be identified by the response to  
treatment. If there is no response to  using a  Beta 2 –agonist more than 
thrice   a week, it  is indicated  to start  treatment  with  corticosteroids. 
Inhalation is either by nebulisation or metered- dose inhaler and 
spacer. Nebulizers are devices that have the capacity to change the  
medications from liquid  into fine moist form  which is easier for deposition 
of medication in the peripheral airways.  
The  nebulizers are of 2 types 
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1. Jet nebulizers  
2. Ultrasonic nebulizers.  
NEBULISER 
 
 
•  Jet nebulisers pass compressed air through the medication to convert 
it into a mist.  
•  Ultrasonic nebulisers pass ultrasound waves through the liquid 
medication to convert it into a mist. 
Metered- dose inhaler is a hand-held pressurised canister that delivers 
a mist of aerosolised medication to the lungs. It is an inexpensive and 
effective method in treating bronchial asthma. The significant advantages of 
aerosol drug delivery are quicker onset of pharmacological action, since the 
drug is being delivered to the peripheral airways
15
, the site which needs 
therapeutic effect and a lower systemic bioavailability, which decreases 
systemic adverse effects.  
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A spacer is an external device that is attached to an MDI. 
METERED DOSE INHALER AND SPACER 
 
Advantages of MDI 
1. It  allows  better drug delivery by enhanced actuation
.
 
2.   It facilitates the coordination of inhalation.   
3. Taste and the smell of the medication can’t be felt because the cloud 
of vapour is so fine.  
4. As the  drug  particles is  in fine form,   they  are carried deep into the 
lung 
The technique for metered dose inhaler (MDI) use is as follows: 
 The cap to be taken off  and the  inhaler to be held  upright. 
  The inhaler to be shaken  before use. 
  The head to be tilted back slightly and patient asked to breathe 
slowly and  completely for 3-5 seconds. 
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 The individual is instructed  to inhale  in slowly  and  simultaneously  
the inhaler  is  pressed down for one  time for releasing  the 
medication; if there is valved holding chamber, inhaler to be press 
down first and then   patient asked to inhale in slowly within  five  
seconds. 
  The individual asked to inhale  in slowly, as uniformly and deeply . 
  Breath is to be held  if possible  for upto ten to fifteen  seconds ; to 
help the medications to reach  deeply into the peripheral airways. 
 The above procedure  is  to be repeated if more than 1 puff (actuation) 
is needed. 
 A gap of one minute to be kept between each puff ; to improve 
penetration of  next puff  into peripheral airways. 
Advantage of  metered- dose inhaler with spacer over nebuliser 
16 
1. portability, multidose delivery capability. 
2. less requirement of maintenance, purchasing & power requirement. 
3. lower bacterial contamination & cross infection. 
4. enhanced efficiency of drug delivery, shorter delivery time  
&improvement in symptoms. 
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5. reduced oral absorption&lack of need for assistance Metered-dose 
inhalers (MDIs) and  spacers  are  equally good  as Nebulizers.  
Advantages  of nebulizers 
Nebulizers  have their ability to deliver larger dosages at a quicker 
rate, in patients with  acute asthma . 
Recent data shows that in both modes of delivery the  lung deposition 
rates are the same. In addition, another trial found that a MDI (with spacer) -
required lower dose for clinical improvement  compared to a nebulizer . 
Side effects of Beta2 agonists-muscle tremor, tachycardia, 
hypokalemia, impaired glucose tolerance, decreased oxidation of fatty acids,  
decreased magnesium, lactic acidosis and  relaxation of uterus. 
Combined inhalation therapy with b2 agonists and oxygen  are  safe  
even when huge  amount of doses are used.  
SALBUTAMOL- MODE OF DELIVERY 
NEBULIZER VERUS MDI-SPACER 
Dhuper S et al conducted a study on 60 adult acute asthma  
patients (29-Spacer and 29-nebulizer).They emphasised  that beta agonist 
delivery with a MDI/disposable spacer combination is an effective and low-
cost alternative to nebulizer delivery for acute asthma
27
.Hendeles L et al 
 demonstrated that higher doses of albuterol delivered by MDI+VHC (4-10 
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puffs per dose) are as effective as 2.5 mg of albuterol sulfate delivered by 
SVN. They also conclude  that MDI+VHC offers practical advantages over 
SVN, including the capacity for home use by the patient, portability, less 
setup time, and lack of need for daily disinfection
28
. Cavkaytar O et al 
showed that asthma exacerbation  treated with pMDIs used through holding 
chambers in emergency room was successful compared  to ordinary method 
of nebulizers
29
.   
Lombardi DM et al compared 90 patients with acute asthma treated 
with MDIs in December 2003 with a similar number treated with wet 
nebulizers in December 2002. Treatment with MDIs resulted in significant 
reduction in  length of stay in the emergency department  and an increase in 
the number of discharges in the first 2 hours of treatment. Patients in the 
MDI group received 87% of the scheduled bronchodilator doses, while 
patients in the wet nebulizer  group received only 37% of the prescribed 
doses.  Patients treated with bronchodilators delivered by MDI improved 
faster and had better fulfillment of treatment standards
30
. 
Colacone et al study concluded that the beneficial effect of 
salbutamol  by MDI and spacer  is similar  to that  by nebulizer in patients 
with acute severe asthma
31
.   
 Theophylline 
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It produces  broncho dilation by inhibiting phosphodiesterase and has 
a narrow therapeutic window. It can be used in acute  severe  asthma rather 
than chronic asthma. 
Anti cholinergics 
Anticholinergic agents are the better drugs for older patients 
compared to younger patients. These are usually used for the non responders 
to the regular doses  of  inhaled steroids in  patients with chronic asthma. Its 
therapeutic role in acute severe asthma is of greater value than    regular  
role in  chronic asthma. 
Anti-inflammatory drugs 
Corticosteroids, mast cell stabilizers, Leukotriene antagonists 
Corticosteroids - At present the first line of medication in  the management 
of chronic asthma is Inhaled glucocorticosteroids. They have advantageous 
effects on the inflammation of walls of  bronchioles  and  hyper- 
responsiveness of the airways  as well as on  clinical features. Budesonide is 
an inhaled corticosteroid with a higher  local activity than systemic effects. 
It can reduce the  chronic inflammatory process of  asthma seen in patients 
with uncontrolled asthma. 
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Budesonide 200 microgram once  daily is used  in mild asthma  by 
inhalation. High-dose inhaled corticosteroid is used  in patients with  
increased  severity of  disease.  
Side-effects-Oropharyngeal candidiasis, Dysphonia, Cough and throat 
irritation, increase in infections and systemic side-effects. 
Mast cell stabilizers (cromolyn sodium, nedocromil)-act  on mast cells  
preventing  release of histamine  by blocking calcium channels. It is useful 
in intermittent, mild asthma and as a prophylaxis in exercise and allergic 
asthma. 
Leukotriene inhibitors  act by blocking 5-lipoxygenase activity. It may  be 
used in combination with inhaled corticosteroids as an add on therapy in the 
treatment of moderate persistent asthma. It is  also effective in aspirin-
induced asthma.  
Immunotherapy 
Specific allergy immunotherapy (desensitisation) is the technique for 
treating Ig E- mediated disease, with increasing doses of  an allergen used in 
order to decrease the sensitivity to that allergen. Its usefulness in asthma is 
controversial. 
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Anti-Immunoglobulin E Ab (Omalizumab)- It acts by  reducing 
circulating levels of IgE .It is useful in reducing  exacerbations in asthma 
and in reducing the requirement of corticosteroids. 
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Protocol of step-up approach in chronic adult asthma 
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AIMS AND OBJECTIVES 
   
To analyse the efficacy of salbutamol administered by a 
nebuliser compared to metered- dose inhaler and spacer in adults 
with acute Asthma.                   
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MATERIALS AND METHODS 
The study was conducted on 52 patients admitted in the Medical ward 
of Government Rajaji Hospital, Madurai. Approval from the hospital ethical 
committee was obtained. 
STUDY DESIGN: 
The study was a cohort study conducted for a period of 6 months  
from May 2012 to October 2012. 
Inclusion criteria: 
  In-patients of medical ward in GRH who have clinical features 
suggestive of bronchial asthma  above 13 years of age  were prospectively 
enrolled after informed consent. 
The diagnosis was based on Pulmonary function tests showing 
decrease in expiratory flow rates :  
 Reduction in  forced expiratory volume over 1 sec (FEV1) and a          
proportionally smaller reduction in the forced vital capacity (FVC) and 
decreased FEV1/FVC ratio (generally <0.70) and reduction in PEFR with 
diurnal variability of Peak Expiratory Flow Rate   > 20 
  Reversibility test as determined by increase in Peak Expiratory Flow 
Rate (PEFR) more than twenty percent ; and  more than twelve percent  or 
200-mL increase in Forced Expiratory Volume in 1 second115 minutes after 
an inhaled  short-acting Beta2-agonist.  
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Exclusion criteria: 
1. Patients <13 yrs age. 
2. Patients with acute respiratory tract infections, COPD and restrictive 
lung disease. 
3. Patients with heart failure, renal failure and hepatic failure  
Blood samples were collected for estimation of Blood urea, Serum 
creatinine and Liver  function  tests. ECG, ECHO,X RAY CHEST PA view 
were taken. 
Methods: 
Fifty two patients with acute asthma in the medical ward of 
Government Rajaji Hospital Madurai were enrolled in the study. All the 
fifty two patients in the study  fulfilled the criteria of American Thoracic 
Society. Patients above the age of thirteen years with Peak Expiratory flow 
rates, Forced Expiratory Volume  in 1 second  below fifty percent of 
predicted value were  eligible for the study. All the patients were on regular 
treatment with bronchodilators and steroids. 
All fifty two patients in the study received bronchodilator- short 
acting Beta 2 agonist, salbutamol. The patients were divided into two groups 
depending on mode of delivery of salbutamol. The first group received 
salbutamol by nebuliser and the second group  by metered dose inhaler and 
spacer. The  twenty six patients in the first group received  0.5ml  of  
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salbutamol (2.5mg ) in 2.5 ml of NS via nebuliser. A face mask was used. 
The time of nebulisation  was nearly 5 minutes and nebulisation was 
stopped  when no suspension was found in the container .The patients in the 
second group received salbutamol via  metered dose inhaler into a spacer in 
puffs  sprayed one at a time at 5 minutes interval(one hundred micro gram  
per puff). The patients were instructed to inhale deeply from the spacer 
following  each puff. The drug was administered in a double blinded 
manner. The  drug dosage was increased in both the groups depending upon 
the  patients’ clinical improvement.  
The following values were  calculated  before medication , after thirty 
minutes of drug delivery, and at the end of the treatment. 
The  variables were PEFR. FEV1, FVC, heart rate, respiratory rate, 
oxygen saturation and drug dosage. The PEFR was measured with a mini-
wright peak flow meter. The highest of three values were recorded. FVC 
and FEV1 were measured using spirometer. Curves of  expiration  were 
recorded at each  time and the maximum value was selected. This was done 
in 3 successive manners according to the American Thoracic society 
guidelines. Oxygen saturation  was calculated using pulse oximeter. Drug 
dosage, heart rate and respiratory rate were also measured. 
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                                                  RESULTS 
Table – 1 
Age Distribution 
Age in years No.of cases Percentage 
< 20 9 17.3 
21 – 40 22 42.3 
> 40 21 40.4 
Total 52 100 
 
Table – 2 
Sex Distribution 
Sex No.of cases Percentage 
Male 33 63.4 
Female 19 36.6 
Total 52 100 
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Table – 3 
Duration of illness 
Duration No.of cases Percentage 
< 10 yrs 10 19.2 
11 – 20 yrs 26 50.0 
21 – 30 yrs 13 25.0 
> 30 yrs 3 5.8 
Total 52 100 
 
Table – 4 
Seasonal Variation
* 
Season No.of cases Percentage 
Yes 39 75 
No 13 25 
Total 52 100 
  
  *Asthmatic Symptoms occurs predominantly in winter 
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Table – 5 
Diurnal Variation
* 
Diurinal No.of cases Percentage 
Yes 40 76.9 
No 12 23.1 
Total 52 100 
 
*Asthmatic symptoms occurs predominantly at night and early 
morning hours. 
Table – 6 
History of Allergy 
 
Allergy No.of cases Percentage 
Yes 42 80.8 
No 10 19.2 
Total 52 100 
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Table – 7 
Family History 
 
Family No.of cases Percentage 
Yes 31 59.6 
No 21 40.4 
Total 52 100 
 
 
Table – 8 
Smoking History 
Smoking No.of cases Percentage 
Yes 14 26.9 
No 38 73.1 
Total 52 100 
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Table – 9 
Frequency of Illness 
 
Frequency No.of cases Percentage 
Daily 20 38.5 
< 2 /week 11 21.1 
> 2/ week 21 40.4 
Total 52 100 
 
Table – 10 
Salbutamol Mode of Delivery 
MDI-S Vs Nebulizer 
Salbutamol MOD No.of cases Percentage 
MDI – S 26 50 
Nebulizer 26 50 
Total 52 100 
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Table – 11 
  Change in  PEFR-MDI -Spacer Vs Nebuliser(30 mts) 
  
PEFR (30 min) Mean SD 
MDI – Spacer (26) 212.31 7.65 
Nebulizer (26) 189.62 9.16 
‘p’ value < 0.001  Significant 
 
  Change in  PEFR-MDI -Spacer Vs Nebuliser( end ) 
   
 
 
 
 
 
There is stastistically  significant  improvement  in PEFR   at 30 mts and at 
end of treatment with the MDI-Spacer group than with the nebulised group. 
 
PEFR (end) Mean SD 
MDI – Spacer  (26) 227.31 10.02 
Nebulizer (26) 210.77 9.77 
‘p’ value < 0.001  Significant 
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Table – 12 
  Change in  FEV1-MDI -Spacer Vs Nebuliser(30 mts) 
FEV1 (30 min) Mean SD 
MDI – Spacer  (26) 1.408 0.011 
Nebulizer (26) 1.371 0.023 
‘p’ value < 0.001   Significant 
 
                  Change in FEV1-MDI -Spacer Vs Nebuliser (end) 
FEV1 (end) Mean SD 
MDI – Spacer  (26) 1.635 0.028 
Nebulizer (26) 1.602 0.015 
‘p’ value < 0.001  Significant 
 
There is stastistically  significant  improvement  in FEV1    at 30 mts and at 
end of treatment with the MDI-Spacer group than with  the  nebulised 
group. 
  
 87 
  Change in  FEV1-MDI -Spacer Vs Nebuliser 
(30 mts vs End) 
 
1.408
1.371
1.635
1.602
1.2
1.25
1.3
1.35
1.4
1.45
1.5
1.55
1.6
1.65
L
it
re
s
FEV1 (30 min) FEV1 (end)
MDI – S  (26) Nebulizer (26)
 
 
 
 
 
 
 
 
 88 
Table – 13 
 
Change in FVC-MDI -Spacer Vs Nebuliser (30 mts) 
 
FVC (30 min) Mean SD 
MDI – Spacer  (26) 1.425 0.025 
Nebulizer (26) 1.396 0.020 
‘p’ value < 0.001   Significant 
                                            
                Change in FVC-MDI -Spacer Vs Nebuliser (end) 
 
 
 
 
 
There is  stastistically  significant  improvement  in FVC   at 30 mts and at 
end of treatment with the MDI-Spacer group than with  the nebulised group. 
FVC (end) Mean SD 
MDI – Spacer  (26) 1.656 0.022 
Nebulizer (26) 1.622 0.013 
‘p’ value < 0.001  Significant 
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Table – 14 
Change in SPO2-MDI -Spacer Vs Nebuliser (30 mts) 
SPO2 (30 min) Mean SD 
MDI – Spacer  (26) 3.92 0.404 
Nebulizer (26) 2.23 0.430 
‘p’ value < 0.001   Significant 
                                         
  Change in SPO2-MDI -Spacer Vs Nebuliser (end) 
SPO2 (end) Mean SD 
MDI – Spacer  (26) 2.23 0.430 
Nebulizer (26) 2.12 0.326 
‘p’ value 0.304  Not Significant 
 
There is statistically significant   improvement in oxygen saturation  at 
30minutes in the MDI-spacer than in the nebuliser group  but there is  
no significant difference at the end of treatment. 
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Table – 15 
Change in  Heart Rate -MDI-Spacer Versus Nebuliser (30 mts) 
 
 
 
 
 
Change in  Heart Rate -MDI-Spacer Versus Nebuliser (end) 
Heart Rate (end) Mean SD 
MDI – S  (26) 9.923 0.272 
Nebulizer (26) 9.423 1.391 
‘p’ value 0.078 Not  Significant 
  
There is no statistically significant difference between MDI-
spacer  and nebuliser groups in the heart rate at 30 minutes and at the 
end of treatment. 
 
Heart Rate (30 min) Mean SD 
MDI – S  (26) 15.00 0.632 
Nebulizer (26) 14.923 0.688 
‘p’ value 0.677  Not   Significant 
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Table – 16 
Change in  Respiratory Rate-MDI-Spacer Versus Nebuliser (30 mts) 
 
 
 
 
 
Change in  Respiratory Rate-MDI-Spacer Versus Nebuliser (30 mts) 
 
RR (end) Mean SD 
MDI – S  (26) 5.077 5.077 
Nebulizer (26) 5.038 0.196 
‘p’ value 0.561 Not   Significant 
 
There is no statistically  significant difference between MDI-
spacer  and nebuliser groups in the respiratory rate at 30 minutes and at 
the end of treatment. 
R R  (30 min) Mean SD 
MDI – S  (26) 14.808 0.567 
Nebulizer (26) 14.538 0.508 
‘p’ value 0.077 Not   Significant 
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Change in  Respiratory Rate-MDI-Spacer Versus Nebuliser 
(30 mts vs End) 
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Table – 17 
 Total dosage of salbutamol-MDI-Spacer versus Nebuliser. 
Drug Doses Mean SD 
MDI – S  (26) 1192.3 146.76 
Nebulizer (26) 4365.3 1836.07 
‘p’ value < 0.001   Significant 
 
The requirement of salbutamol in MDI-spacer is  significantly lower 
than nebulizer as suggested by p value less than .001. 
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RESULTS 
A total of 52 patients with acute Bronchial asthma who received 
salbutamol therapy participated in the study. The patients were divided into 
2 groups: 26 (50%) patients in the MDI-Spacer group and 26 (50%) patients 
in the Nebuliser group. The baseline characteristics of over all cohort were 
expressed in percentage. Age distribution was 17.3%(<20yrs),42.3%(21-
40yrs), 40.4%(>40yrs) as shown in Table 1.Sex distribution was males  
(63.4%) and females( 36.6% )as shown in Table 2.Duration of illness was 
19.2%(10yrs),50%(11-20yrs),25%(21-30yrs) and 5.8%(>30yrs) as shown in 
Table 3.Table  4. shows 75% of patients with seasonal variation and 25% 
with no seasonal variation. Diurnal variation was demonstrated in76.9%  of 
patients but  not in the rest 23.1% ,as illustrated in Table 5.As per Table 6,a 
positive history of allergy is seen in  80.8% and  is negative in 19.2%. As 
shown in Table 7, 59.6% of patients  have a positive family history and 
40.4% do not. 26.9% of patients had a  history of smoking and 73.1% were 
non smokers(Table 8). The frequency of illness was  
38.5%(daily),21.1%(<2/week) and 40.4%(>2/ week) as depicted in Table 9. 
The two treatment groups were comparable as regards change in 
PEFR, FEV1, FVC, Oxygen saturation, heart rate, respiratory rate and drug 
dosage at thirty  minutes and at the end of  treatment. Mean 
PEFR,FEV1,FVC and oxygen saturation values improved significantly over 
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base line values in both nebuliser and MDI-spacer groups. They were 
expressed as mean and standard deviation. The magnitude of improvement   
in PEFR  at 30 minutes  were 212.31 ±7.65 in the MDI-Spacer group and 
189.62±9.16 in the nebulised group and at the end of treatment 
227.31±10.02 in the MDI-spacer group and 210.77±9.77 in the nebulised 
group(table-11).PEFR has statistically significant difference (p <0.001) in  
MDI-spacer than nebulised group at 30 mts and at the end of treatment. 
Change in FEV1 in the MDI-spacer group and nebulised group at 30 
minutes were 1.408±0.011  and 1.371±0.023  and at the end of treatment  
were 1.635±0.028  and 1.602±0.015 respectively(table-12). FEV1 has  
statistically significant difference (p <0.001) in  MDI-spacer than nebulised 
group at 30 mts and at the end of treatment. The same pattern was held for  
change in FVC in the MDI-spacer group and nebulised group;the values at 
30 minutes were 1.425±0.025  and 1.396±0.020  and at the end of treatment  
were 1.656±0.022  and 1.622± 0.013 respectively(table-13). FVC has 
statistically significant difference (p <0.001) in  MDI-spacer than nebulised 
group at 30 mts and at the end of treatment. Change in oxygen saturation at 
30mts was 3.92±0.404 (MDI-Spacer) and 2.23±0.430 (nebulised group) .It 
was significant with p<0.001 at 30mts.At the end of treatment the 
corresponding values were 2.23±0.430(MDI-spacer) and 2.12± 
.33)(nebulised group)Table 14.There was no  statistically significant 
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difference (p 0.304). The change in heart rate at 30 mts and at the end of 
treatment were 15±0.63 and 9.92±0.27 in the spacer group and 14.92±0.69 
and 9.42±1.40 in the nebulised group  respectively(p 0.677)(table-15), 
Change in  Respiratory rate   at 30 mts and at the end of treatment 
were14.81±0.57  and 5.07±5.07 in the spacer group and 14.54±0.51and 
5.04±0.19 in the nebulised group .p values were 0.07(30mts) and 
0.5619(end of treatment)(table-16). Heart rate and respiratory rate changes 
were not significantly affected by  the mode of delivery. Drug dosage in the 
MDI group was 1192.3±146.76 and 4365.3±1836.07 in the nebulised group, 
it was statistically significant,with p<0.001.(table-17)  
Statistical analysis: 
Analysis was performed with SIGMA  STAT  VERSION 3.5  
statistical package. All continuous variables were presented as mean 
±standard deviation if they were normally distributed. One way Anova  
Analysis and Chi square test was performed  to study the comparison 
between  nebuliser and MDI -spacer. Differences in the normally distributed 
variables were assessed using  t-test and  paired t-test for dependent 
variables. Comparisons between the two individual groups were performed 
using the unpaired t-test (parametric) All tests were two-sided and a 
probability value of p < 0.05 was considered as significant. 
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DISCUSSION 
Patients with Acute asthma arrive at our hospital relatively rapidly 
due to its central location and most of the patients could obtain maximum 
and rapid benefit by bronchodilators  provided by government free of cost. 
Several modes of  therapy for acute exacerbation of asthma have been 
developed which differ in terms of effectiveness, complexity and cost. 
Currently, the most relevant treatment options are: Bronchodilators(short 
acting beta 2 agonist)  (salbutamol, terbutaline, fenoterol), Anticholinergics 
and Corticosteroids. 
Short acting  beta 2 agonist is the treatment option which quickly 
relieves bronchospasm .Reversibility with bronchodilators predicts a good 
outcome in acute bronchial asthma. It can be delivered by Nebuliser and 
MDI with spacer. Now-a-days MDI and spacer is useful in acute asthma. 
The clinical significance of MDI and spacer lies is the  amount of drug that 
reaches lower airways. It depends upon the aerodynamic mass median 
diameter. According to Mazhar SH et al study
26
, in nebuliser only ten 
percent of the dose reaches the lungs after leaving the nebuliser. In contrast, 
in MDI with spacer approximately twenty percent of drug dosage is  
deposited in the peripheral airways. Spacers are known to improve the 
compliance of the patient, increase the efficacy of drug delivery and reduce 
oral absorption compared to MDI without spacers or holding chamber. Their 
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use is particularly valuable in patients who have poor timing and do  not  
adequately  coordinate  inhalation  from  an MDI with the actuation of 
the device. MDI requires less drug dosage compared to a nebuliser. 
Kenneth B. Newman et al 
22
who reported there was a statistically 
greater improvement in peak flow rates in the MDI/spacer group vs 
nebulized group  (126.8 vs 111.9 L/minute, respectively; p value equal to  
.002),  had showed  a lesser total  salbutamol  dosage  (one thousand and 
hundred twenty five micro gm and  six thousand and seven hundred  micro. 
gm, respectively; p value less than 0.001), and showed a maximum  
improvement in Sa O2 (p value equal to  0.043).According to RODRIGO et 
al 
23
 study there was a significant improvement in PEFR, FEV1,FVC at 30 
mts and at the end of treatment in MDI spacer group compared to nebulised 
group. The magnitude of improvement of PEFR at 30 minutes was  (77+/-
46Litre/minute)  in  the nebuliser category and (83+/-61 Litre/minute) in  
the Metered Dose Inhaler-spacer  category ; (p value  less than .01)and at 
the end of therapeutic trial(112+/-52Litre/minute  in the nebuliser category 
and 119 Litre /minute)  in the Metered Dose Inhaler –spacer category  ;(p 
value  less than 0.001) .The improvement of  average  Forced Vital Capacity  
was significant over pretreatment values in both nebuliser and Metered 
Dose Inhaler-spacer categories;(p value  less than .001);the values  at thirty 
mts being ( .7+/- .4 Litres and .7+/-.6 Litres), respectively for nebulised and 
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MDI spacer; (p value  less than  .01) and (1+/- .6Litres and 1.0+/-0 .7 
Litres,) respectively; (p value less than  .001) after the cessation of  therapy. 
Similar changes in measurements was held for  FEV1. At  thirty minutes, 
FEV1  increased by (0.5+/-0.3Litres) in  nebuliser category  and (0.6+/-0.5 
Litres) in  Metered Dose Inhaler-spacer category (p value  less than  .01). At  
the  end of therapeutic trial Forced Expiratory Volume in 1 second increased  
(.8 +/- .4 Litres) in  nebuliser category   and  (.9 +/- .5 Litres) in   Metered 
Dose Inhaler-spacer  category (p value less than .001) But there was no 
statistically  significant difference in heart rate between the nebulised and 
Metered Dose Inhaler-Spacer group. Dosage of salbutamol in Metered Dose 
Inhaler group was lower compared to nebulised group. 
Idris et al
25
 reported that a  significant improvement occurs in average 
Forced Expiratory Volume in 1second  at thirty  minutes  (p value less than 
.02) and at  sixty minutes  (p value less than .02)  and in  maximum average 
( p value is  less than  .001).  
According to Christopher J Cates
24
, statistically significant 
differences were seen between  the two categories in baseline pulmonary 
function. Results were  presented  only as change in Pulmonary function  
from the baseline, and this  favoured the spacer. There were  no significant 
differences demonstrated between the two categories  in their  outcomes  : 
change in respiratory rate and oxygen saturation. 
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Limitations 
Some patients did not respond to short acting beta2 agonists even 
after maximum doses were given, they were switched over to systemic 
medications like corticosteroids. Others were not able to perform pulmonary 
function tests before the medication because of poor compliance. Patients  
presenting with Status asthmaticus and Near fatal asthma required life 
saving measures  apart  from  routine medications. Reversibility with 
Bronchodilators did not occur with a few patients, who had associated  
chronic obstructive pulmonary disease or had developed chronic 
inflammatory process in asthma leading  to irreversible air flow obstruction. 
These patients were not included in the study. 
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CONCLUSION 
1. Base line characters were not comparable in the study. The patients 
were  equally divided into two groups for better comparison. 
2. PEFR improvement was significant at 30 mts and at end of treatment 
with the MDI-Spacer group than the nebulised group. 
3. FEV1 improvement was also significant at 30 mts and at end of 
treatment with the MDI-Spacer group than the nebulised group. 
4. FVC improvement was also significant at 30 mts and at end of 
treatment with the MDI-Spacer group than the nebulised group. 
5. For oxygen saturation, the magnitude of improvement was significant 
at 30 mts in the spacer group, but at the end of treatment the 
improvements were similar in both the groups. 
6. Heart rate and respiratory rate improvement was present in both 
groups and were similar in both  at 30 mts and at the end of treatment. 
7.  Clinical improvement was achieved even at a lower dosage  in the 
MDI-spacer group compared to nebuliser group. 
  Salbutamol administration by metered dose inhaler and spacer is as 
efficacious  as  nebuliser in adults with acute asthma. Now-a-days Metered 
Dose Inhaler and Spacer is the best alternative to nebuliser in acute asthma. 
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CASE  PROFORMA 
 
 Name:                                                                        Sex: 
 Age:                                                                           Occupation: 
 CLINICAL PROFILE: 
   Difficulty in breathing 
   Diurnal variation 
   Seasonal variation 
   Cough with expectoration 
 Total duration of illness:                         Frequency of  illness: 
 Smoking  history:                                    Family history: 
Allergic history:                                        Treatment history: 
System Examination:Level of consciousness                     Cyanosis                                      
Able  to speak in words         Pulse rate                               Respiratory rate                  
Pulsus paradoxus                        Blood pressure                            JVP 
Action of accessory muscle of respiration- 
 Examination of  CVS-                       P/A- 
                             RS-                         CNS- 
INVESTIGATION:   
Blood urea :                                             Serum creatinine: 
ECG:                                                            ECHO: 
X RAY CHEST PA view: 
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Liver  function  test: 
Serum total bilirubin-                 SGOT-                      SGPT-                    
S.Alkaline phosphate-                    
 
Pulmonary function test:    
Administration of salbutamol:Nebuliser/Metered dose inhaler and spacer 
     PFT 
 
         0mts           30mts            End 
 1.PEFR 
 
   
 2.FEV1 
 
   
 3.FVC 
 
   
 4.Oxygen  
    saturation 
   
 5.Drug dosage 
 
   
 6.Pulse rate 
 
   
 7.Respiratory 
rate 
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                                              ABBREVIATIONS 
 
MDI-S - Metered Dose Inhaler and Spacer. 
PEFR  - Peak Expiratory Flow Rate. 
FEV1  - Forced Expiratory Volume in One Second. 
FVC  - Forced Vital Capacity. 
VHC  - Valved Holding Chamber. 
PFT  - Pulmonary Function Test. 
SVN  - Small Volume Nebuliser. 
COPD - Chronic Obstructive Pulmonary Disease. 
ROI  - Reactive Oxygen Intermediates. 
IL  - Interleukin. 
Pa O2  - Partial Pressure of Oxygen. 
Pa CO2 - Partial Pressure of Carbon dioxide. 
Sa O2   -  Oxygen Saturation. 
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1 40 M 20 170 yes no no no no daily 
MDI-
S 280 480 500 200 220 0.87 2.25 2.53 1.38 1.66 1.3 2.7 3 1.40 1.68 93 97 99 4 2 140 126 116 14 10 40 25 20 15 5 1000 
2 43 f 33 154 yes yes yes no no daily 
MDI-
S 300 510 530 210 230 0.76 2.16 2.40 1.40 1.64 1.2 2.6 2.8 1.4 1.7 92 96 98 4 2 146 131 121 14 10 45 30 25 15 5 1200 
3 35 f 18 160 no yes yes yes no >2/wk 
MDI-
S 290 490 500 200 210 0.56 1.96 2.18 1.40 1.62 0.8 2.3 2.5 1.4 1.6 93 97 99 4 2 140 126 116 14 10 48 33 28 15 5 1000 
4 32 f 15 165 yes yes yes no n0 >2/wk neb 310 500 510 190 200 0.9 2.3 2.5 1.4 1.6 1.4 2.8 3 1.4 1.6 93 95 98 2 3 140 125 110 15 10 42 28 23 14 5 5000 
5 30 m 5 160 no yes no no yes <2/wk neb 300 490 510 190 210 1 2.3 2.5 1.3 1.6 1.4 2.7 2.6 1.4 1.6 94 96 98 2 2 143 128 118 15 10 44 30 25 14 5 2500 
6 60 m 15 170 yes no no yes no daily 
MDI-
S 280 480 490 200 210 0.9 2.3 2.5 1.4 1.6 1.3 2.7 2.9 1.4 1.7 92 96 98 4 2 140 125 115 15 10 40 25 20 15 5 1100 
7 55 m 25 160 no yes no no yes daily neb 290 490 500 200 210 0.8 2.2 2.4 1.4 1.6 1.2 2.6 2.8 1.4 1.6 93 96 99 3 3 142 128 117 14 11 44 29 24 15 5 5000 
8 13 m 12 145 yes yes yes yes no <2/wk 
MDI-
S 180 390 420 210 240 0.8 2.2 2.5 1.4 1.6 1.2 2.7 2.9 1.4 1.7 91 95 98 4 3 138 124 114 14 10 48 33 28 15 5 1200 
9 17 m 12 150 yes yes yes no no >2/wk 
MDI-
S 200 420 430 220 230 0.7 2.1 2.4 1.4 1.7 1.1 2.6 2.7 1.4 1.6 93 97 99 4 2 135 120 110 15 10 52 36 31 16 5 1300 
10 20 f 5 155 yes yes no yes no <2/wk neb 200 380 440 180 240 0.8 2.2 2.4 1.4 1.6 1.2 2.6 2.8 1.4 1.6 94 96 98 2 2 140 125 115 15 10 44 29 24 15 5 5000 
11 60 m 30 160 no yes yes yes yes >2/wk neb 250 450 470 200 220 1 2.4 2.6 1.4 1.6 1.4 2.8 3 1.4 1.6 93 96 98 3 2 130 115 105 15 10 40 26 21 14 5 2500 
12 55 f 20 165 yes yes yes no no daily 
MDI-
S 290 490 500 200 210 0.7 2.1 2.3 1.4 1.6 1 2.5 2.7 1.4 1.6 92 96 99 4 3 130 115 105 15 10 44 29 24 15 5 1200 
13 56 f >25 165 yes no yes yes no daily neb 300 490 520 190 220 0.9 2.3 2.5 1.4 1.6 1.3 2.7 2.9 1.4 1.6 92 94 96 2 2 146 132 122 14 10 48 34 29 14 5 5000 
14 42 m 15 170 no yes yes no no <2/wk neb 310 490 540 180 230 1 2.4 2.6 1.4 1.6 1.5 2.8 3.1 1.4 1.6 93 96 98 3 2 140 124 114 16 10 40 25 20 15 5 2500 
15 31 m >25 165 yes yes yes yes yes >2/wk 
MDI-
S 320 530 540 210 220 0.7 2.1 2.4 1.4 1.6 1.2 2.7 2.9 1.4 1.7 93 96 98 3 2 136 121 111 15 10 44 29 24 15 5 1100 
16 23 m >10 160 yes yes yes yes no >2/wk 
MDI-
S 270 490 500 220 230 0.8 2.2 2.4 1.4 1.6 1.2 2.6 2.8 1.4 1.6 91 95 97 5 2 140 126 116 14 10 55 40 34 15 6 1200 
17 46 m >20 170 yes no yes no yes daily neb 330 410 440 180 210 0.6 2 2.2 1.4 1.6 0.9 2.3 2.5 1.4 1.6 92 94 96 2 2 140 125 116 15 9 44 30 25 14 5 5000 
18 25 f >20 150 yes yes yes yes no >2/wk 
MDI-
S 250 470 490 220 240 0.6 2 2.3 1.4 1.6 1 2.4 2.7 1.4 1.7 93 97 99 4 2 135 125 115 15 10 50 35 30 15 5 1300 
 113 
19 40 m >20 170 no yes no no no >2/wk neb 300 510 520 210 220 0.7 2.1 2.2 1.4 1.6 1 2.5 2.6 1.4 1.6 95 97 99 2 2 138 124 114 14 10 46 31 26 15 5 7500 
20 17 f 3 154 yes yes yes yes no >2/wk 
MDI-
S 250 470 480 220 230 1 2.4 2.6 1.4 1.6 1.4 2.9 3.1 1.4 1.7 93 96 99 3 3 140 126 116 14 10 46 32 27 14 5 1000 
21 53 f >20 160 yes no yes yes no daily 
MDI-
S 320 530 560 210 240 1 2.4 2.6 1.4 1.6 1.5 2.9 3.1 1.4 1.6 92 96 98 4 2 140 
125       
116 116 15 9 44 28 23 16 5 1000 
22 53 m >15 168 yes no yes no yes daily neb 290 480 500 190 210 0.9 2.3 2.5 1.4 1.6 1.4 2.8 3 1.4 1.6 95 97 99 2 2 134 119 110 15 9 38 23 17 15 6 2500 
23 15 m >12 150 yes yes yes yes no >2/wk 
MDI-
S 250 470 480 220 230 0.9 2.4 2.6 1.4 1.7 1.4 2.8 3.1 1.4 1.7 93 97 99 4 2 136 121 111 15 10 40 25 20 15 5 1200 
24 42 m 10 170 no yes yes no no daily neb 340 520 540 180 200 0.8 2.2 2.5 1.3 1.6 1.4 2.7 3 1.4 1.6 93 95 97 2 2 130 115 105 15 10 38 24 18 14 5 5000 
25 31 m >20 162 yes yes yes yes no >2/wk neb 380 580 590 200 210 1 2.4 2.6 1.4 1.6 1.6 2.9 3.2 1.4 1.6 92 94 96 2 2 135 124 114 14 10 38 23 18 15 5 2500 
26 42 m 18 168 yes yes yes no yes >2/wk 
MDI-
S 270 480 490 210 220 0.9 2.3 2.6 1.4 1.7 1.4 2.8 3.1 1.4 1.7 92 96 98 4 2 138 123 113 15 10 38 22 17 15 5 1100 
27 40 f 15 150 no yes no no no daily 
MDI-
S 310 520 540 210 230 0.8 2.2 2.4 1.4 1.6 1.3 2.7 2.9 1.4 1.7 93 97 99 4 2 140 124 114 16 10 48 33 28 15 5 1300 
28 32 f 15 158 yes no yes yes no daily 
MDI-
S 300 500 510 200 210 0.8 2.2 2.4 1.4 1.6 1.2 2.6 2.8 1.4 1.6 93 97 99 4 2 130 116 106 16 10 46 32 27 14 5 1200 
29 38 f 10 167 no yes yes yes no daily neb 320 510 520 190 200 0.9 2.3 2.5 1.4 1.6 1.3 2.7 2.9 1.4 1.6 94 96 98 2 2 142 128 118 14 10 40 25 20 15 5 5000 
30 32 m 8 162 yes yes yes yes no >2/wk neb 310 490 520 180 210 1 2.3 2.6 1.3 1.6 1.4 2.8 3 1.4 1.6 94 96 98 2 2 145 130 120 15 10 38 23 18 15 5 7500 
31 58 m 18 168 yes no yes yes yes <2/wk 
MDI-
S 290 500 510 210 220 0.9 2.3 2.5 1.4 1.6 1.3 2.7 3 1.4 1.7 93 97 99 4 2 142 128 118 14 10 40 25 5 15 5 1100 
32 53 m 20 164 no yes yes yes no >2/wk neb 300 500 510 200 210 0.8 2.2 2.4 1.4 1.6 1.2 2.6 2.8 1.4 1.6 94 97 99 3 3 144 128 118 16 10 42 28 29 14 5 2500 
33 16 m 13 150 yes yes yes yes no >2/wk 
MDI-
S 200 410 440 210 240 0.9 2.3 2.5 1.4 1.6 1.2 2.7 2.9 1.4 1.7 92 96 99 4 3 132 117 108 15 9 46 31 26 15 5 1200 
34 18 m 15 154 yes yes yes yes no <2/wk 
MDI-
S 280 500 510 220 230 0.8 2.2 2.4 1.4 1.7 1.2 2.6 2.8 1.4 1.7 93 97 99 4 2 1 127 117 15 10 50 35 30 15 5 1000 
35 25 f 10 153 yes yes no no no >2/wk neb 290 470 490 180 200 0.8 2.2 2.4 1.4 1.6 `1.12 2.5 2.8 1.4 1.6 94 96 98 2 2 144 129 119 15 10 42 27 22 15 5 5000 
36 55 m 35 164 yes no yes yes yes daily neb 280 480 490 200 210 0.9 2.3 2.5 1.4 1.6 1.4 2.8 3 1.4 1.6 94 97 99 3 2 140 125 115 15 10 42 28 23 14 5 7500 
37 52 f 30 163 no yes no no no daily 
MDI-
S 300 510 520 210 220 0.9 2.3 2.4 1.4 1.5 1.3 2.6 3 1.4 1.6 92 96 99 4 3 130 116 106 14 10 46 31 26 15 5 1400 
38 48 f 20 160 yes yes yes yes no >2/wk neb 310 500 530 190 220 0.8 2.2 2.4 1.4 1.6 1.2 2.6 2.8 1.4 1.6 94 96 98 2 2 140 124 115 16 9 46 32 27 14 5 2500 
39 38 m 10 168 yes yes yes no yes >2/wk neb 320 500 520 180 200 1 2.3 2.6 1.4 1.6 1.4 2.7 3 1.4 1.6 94 97 99 3 2 142 127 118 15 9 38 23 18 15 5 5000 
40 28 m 20 163 yes yes yes yes no <2/wk 
MDI-
S 330 550 560 220 230 0.8 2.2 2.4 1.4 1.6 1.2 2.5 2.8 1.3 1.7 94 97 99 3 2 138 123 113 15 10 46 32 27 14 5 1400 
41 25 m 15 163 yes yes yes yes no <2/wk 
MDI-
S 290 510 520 220 230 0.8 2.3 2.5 1.4 1.6 1.2 2.7 2.9 1.4 1.6 92 97 99 5 2 140 124 114 16 10 45 30 25 15 5 1500 
 114 
42 43 m 18 168 yes no yes yes no daily neb 340 520 550 180 210 0.8 2.2 2.4 1.4 1.6 1.2 2.6 2.8 1.4 1.6 93 95 97 2 2 145 130 121 15 9 40 25 20 15 5 2500 
43 28 f 20 154 yes yes yes yes no <2/wk 
MDI-
S 300 520 540 220 240 0.8 2.2 2.5 1.4 1.6 1.2 2.6 2.9 1.4 1.7 92 96 98 4 2 140 126 116 14 10 45 30 25 15 5 1300 
44 43 m 25 166 no yes no no yes daily neb 300 500 510 200 210 0.9 2.3 2.4 1.4 1.6 1.2 2.7 2.8 1.4 1.6 94 96 98 2 2 138 124 114 14 10 48 34 33 14 5 2500 
45 15 f 5 150 yes yes yes yes no <2/wk 
MDI-
S 290 510 520 220 230 0.9 2.4 2.6 1.4 1.6 1.4 2.9 3.1 1.4 1.7 92 95 98 3 3 1 119 109 16 10 44 30 25 14 5 1000 
46 50 f >30 164 yes no yes yes no daily 
MDI-
S 320 530 560 210 240 1 2.4 2.6 1.4 1.6 1.5 2.9 3.1 1.4 1.6 93 97 99 4 2 145 130 120 15 10 46 30 25 16 5 1300 
47 56 m >20 166 no yes yes no yes daily neb 300 490 510 190 210 0.9 2.3 2.5 1.4 1.6 1.4 2.8 3 1.4 1.6 94 96 98 2 2 148 134 125 14 9 40 26 20 14 6 6000 
48 17 m >15 154 yes yes yes yes no >2/wk 
MDI-
S 280 500 510 220 230 0.9 2.3 2.6 1.4 1.7 1.3 2.8 3 1.4 1.7 93 97 99 4 2 130 115 105 15 10 38 23 18 15 5 1400 
49 40 m >15 168 yes no yes no yes daily neb 340 520 540 180 200 0.9 2.2 2.5 1.4 1.6 1.3 2.7 2.9 1.4 1.6 94 96 98 2 2 140 125 115 15 10 40 25 20 15 5 2500 
50 30 m >20  160 yes yes yes yes no >2/wk neb 380 580 590 200 210 1 2.3 2.5 1.4 1.6 1.4 2.8 3 1.4 1.6 95 97 99 2 2 148 130 126 16 10 40 26 21 14 5 2500 
51 37 f 10 154 yes yes yes no no <2/wk neb 360 540 560 180 200 0.9 2.3 2.5 1.4 1.6 1.3 2.8 3 1.4 1.6 93 95 97 2 2 143 128 123 15 5 44 29 25 15 5 7500 
52 30 m 20 160 yes yes yes yes yes >2/wk neb 320 510 530 190 210 0.9 2.3 2.5 1.4 1.6 1.4 2.8 3 1.4 1.6 94 96 98 2 2 138 122 117 16 5 48 33 27 15 5 5000 
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